Jennifer E. Mason

Learn More
OBJECTIVE While metformin is generally accepted as the first-line agent in treatment of type 2 diabetes, there are insufficient evidence and extensive debate about the best second-line agent. We aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. (More)
BACKGROUND Statins are an important part of the treatment plan for patients with type 2 diabetes. However, patients who are prescribed statins often take less than the prescribed amount or stop taking the drug altogether. This suboptimal adherence may decrease the benefit of statin initiation. OBJECTIVE To estimate the influence of adherence on the(More)
OBJECTIVES Glycemic control can lower the risk of diabetes-related complications, and delayed treatment intensification can impede optimal diabetes care. This study examines trends in hyperglycemia treatment intensification between 2002 and 2010. STUDY DESIGN Retrospective secondary data analysis of a large national administrative data set of privately(More)
BACKGROUND Several guidelines to reduce cardiovascular risk in diabetes patients exist in North America, Europe, and Australia. Their ability to achieve this goal efficiently is unclear. METHODS AND FINDINGS Decision analysis was used to compare the efficiency and effectiveness of international contemporary guidelines for the management of hypertension(More)
We present a Markov decision process (MDP) model to determine the optimal timing of blood pressure and cholesterol medications. We study the use of our model for a high-risk population of patients with type 2 diabetes; however, the model and methods we present are applicable to the general population. We compare the optimal policies based on our MDP to(More)
We are grateful for the comments from Messori and Bellia (1) and those of Bae et al. (2) regarding our article (3). We hope the following response will clarify the questions they raised. Messori and Bellia (1) pointed out that the incremental cost-effectiveness ratio (ICER) is preferred over the absolute cost-effectiveness ratio. We agree, and it is worth(More)
Medical decisions often involve tradeoff among competing criteria. For example, patients with third-party health insurance are primarily concerned about maximizing their quality-adjusted lifespan, since the majority of the cost burden typically falls on the third-party payer. On the other hand, third-party payers are incented to minimize total(More)
In 2010, over 200,000 women in the U.S. were diagnosed with invasive breast cancer, and an estimated 17% of those women died from the disease, according to the Centers for Disease Control and Prevention (CDC). Also in 2010, the CDC reported that 12.6 million women had diabetes, the seventh leading cause of death in the U.S. Recent medical literature(More)
  • 1